• Login
    • Join
  • FOLLOW:
  • Subscribe Free
    • Magazine
    • eNewsletter
    Checkout
    • Magazine
    • News
    • Manufacturing
    • Packaging
    • Development
    • Compliance
    • Top 20
    • Directory
    • Solution Center
    • Events
    • More
  • Magazine
  • News
  • Manufacturing
  • Packaging
  • Development
  • Compliance
  • Top 20
  • Directory
  • Solution Center
  • Events
  • Current / Back Issue
    Features
    Editorial
    Columns
    Digital Edition
    eNewsletter Archive
    Our Team
    Editorial Guidelines
    Subscribe Now
    Advertise Now
    Top Features
    Reducing the Risk of Comparator Sourcing

    Clinical Data Management

    Leveraging AI/ML Analytics for Better Clinical Development Decisions

    What is a Manufacturing Ecosystem and Why are They Growing?

    Get Smart: Integrating PAT Data into Existing Biotech Data Infrastructures
    Breaking News
    Online Exclusives
    Industry News
    Collaborations & Alliances
    Promotions & Moves
    Trials & Filings
    Financial Reports
    Bio News & Views
    Custom Sourcing News
    Packaging & Tracking
    CRO News
    Live From Shows
    Top News
    Meiji Seika Pharma, Adcock Ingram Pharma Complete Construction of New Manufacturing Facility

    JSR Life Sciences Consolidates KBI Biopharma and Selexis SA

    Charles River, Wheeler Bio Partner to Operate RightSource Laboratory

    Cellular Origins Launches Robotic Platform for Scalable Manufacture of Advanced Therapies

    Waters Corp. Acquires Light Scattering Company Wyatt Technology
    APIs
    Aseptic Processing
    Cleaning Validation
    Clinical Trial Materials
    Cytotoxics and High Potency Manufacturing
    Equipment
    Excipients
    Extractables and Leachables
    Facilities
    Fill/Finish
    Lyophilization
    Parenterals
    Process Development
    Process Validation
    Risk Management
    Scale-up/ Technology Transfer
    Solid Dosage/ Creams/ Ointments

    How CDMOs Can Leverage Contract Terms to Facilitate Payment

    Meiji Seika Pharma, Adcock Ingram Pharma Complete Construction of New Manufacturing Facility

    JSR Life Sciences Consolidates KBI Biopharma and Selexis SA

    Charles River, Wheeler Bio Partner to Operate RightSource Laboratory

    Cellular Origins Launches Robotic Platform for Scalable Manufacture of Advanced Therapies
    Capsules
    Cold Chain Management
    Injectables
    Logistics
    Serialization
    Solid Dosage / Semi-solids
    Supply Chain
    Vials

    Traceability & 2D Barcodes

    Complex in Complex – New Hopes for Better Drug Delivery in Topical Dosage Formulation

    Proactive Resource Group Offers DSCSA Services for Pharma Companies

    Catalent Adds New Cryogenic Capabilities at Japanese Facility

    TraceLink, PharmaLink Partner to Simplify DSCSA Compliance
    Analytical Services
    Bioanalytical Services
    Bioassay Developement
    Biologics, Proteins, Vaccines
    Biosimilars
    Chemistry
    Clinical Trials
    Drug Delivery
    Drug Development
    Drug Discovery
    Formulation Development
    Information Technology
    Laboratory Testing
    Methods Development
    Microbiology
    Preclinical Outsourcing
    R&D
    Toxicology

    How CDMOs Can Leverage Contract Terms to Facilitate Payment

    Meiji Seika Pharma, Adcock Ingram Pharma Complete Construction of New Manufacturing Facility

    JSR Life Sciences Consolidates KBI Biopharma and Selexis SA

    Charles River, Wheeler Bio Partner to Operate RightSource Laboratory

    Cellular Origins Launches Robotic Platform for Scalable Manufacture of Advanced Therapies
    Filtration & Purification
    GMPs/GCPs
    Inspections
    QA/QC
    Regulatory Affairs
    Validation

    FDA 2023 Inspection Roadmap: Is “Readiness” in Your Annual Objectives?

    FDA Watch: Are You Suitably Staffed?

    FDA Watch: Is Your Supply Chain at Risk?

    FDA Watch: CDER to Launch Guidance Snapshot Pilot Program

    "3 Key Trends" with Paul Josephs
    Companies
    Categories
    Corporate Capabilities
    Add New Company
    Contract Service Directory Companies
    Quotient Sciences

    Almac Group

    LOTTE BIOLOGICS

    TaiMed Biologics

    Lannett CDMO
    Companies
    News Releases
    Posters
    Brochures
    Services
    Videos
    Case Study
    White Papers
    Jobs
    Contract Service Directory Companies
    Quotient Sciences

    Almac Group

    LOTTE BIOLOGICS

    TaiMed Biologics

    Lannett CDMO
    Webinars
    Live From Shows
    • Magazine
      • Current / Back Issue
      • Features
      • Editorial
      • Columns
      • Editorial Guidelines
      • Subscribe Now
      • Advertise Now
      • Enewsletter Archive
      • Digital Edition
    • Directory
      • Companies
      • Categories
      • Corporate Capabilities
      • Add Your Company
    • Manufacturing
      • APIs
      • Aseptic Processing
      • Cleaning Validation
      • Clinical Trial Materials
      • Cytotoxics and High Potency Manufacturing
      • Equipment
      • Excipients
      • Extractables and Leachables
      • Facilities
      • Fill/Finish
      • Lyophilization
      • Parenterals
      • Process Development
      • Process Validation
      • Risk Management
      • Scale-up/ Technology Transfer
      • Solid Dosage/ Creams/ Ointments
      • cGMP Manufacture
    • Packaging
      • Capsules
      • Cold Chain Management
      • Injectables
      • Logistics
      • Serialization
      • Solid Dosage / Semi-solids
      • Supply Chain
      • Vials
    • Development
      • Analytical Services
      • Bioanalytical Services
      • Bioassay Developement
      • Biologics, Proteins, Vaccines
      • Biosimilars
      • Chemistry
      • Clinical Trials
      • Drug Delivery
      • Drug Development
      • Drug Discovery
      • Formulation Development
      • Information Technology
      • Laboratory Testing
      • Methods Development
      • Microbiology
      • Preclinical Outsourcing
      • R&D
      • Toxicology
    • Compliance
      • Filtration & Purification
      • GMPs/GCPs
      • Inspections
      • QA/QC
      • Regulatory Affairs
      • Validation
    • Top 25 Pharma & BioPharma
    • Contract Pharma Direct
    • Breaking News
    • Online Exclusives
    • Slideshows
    • Experts Opinions
    • Surveys
      • Outsourcing Survey
      • Salary Survey
    • Glossary
    • Videos
    • White Papers
    • Podcasts
    • Infographics
    • Microsites
      • Companies
      • News Releases
      • Posters
      • Brochures
      • Services
      • Videos
      • Case Study
      • White Papers
    • Contract Pharma Conference
      • Contract Pharma Conference
      • Speakers
      • Exhibitors
      • Conference Sessions
    • eBook
    • Webinars
    • Events
      • Industry Events
      • Live from Show Events
      • Webinars
    • Classifieds / Job Bank
      • Classifieds
      • Job Bank
    • About Us
      • About Us
      • Contact Us
      • Advertise With Us
      • Privacy Policy
      • Terms of Use
    Bio News & Views

    Whose Platform Is It Anyway?

    Both Sides of the Table

    E. Morrey Atkinson, Ph.D.01.23.12

    Here’s the conundrum: As every manufacturing manager knows, offering flexibility can be expensive. To design and build a facility that can accommodate any product, using all available technology, would be cost prohibitive. The capital required to “be all things to all products” would make a facility expensive, unwieldy and inefficient. Therefore, manufacturers of biopharmaceuticals have moved to common platforms, with industry-standard choices such as expression systems, standard unit operations, and even final product container/closure systems. Throughout the value chain of biopharma production, standardization has become the goal. On the surface, this standardization leads to efficiency. Regulatory agencies have become accustomed to seeing certain consistent technologies, resulting in reduced regulatory risk. A proven technology enables a manufacturer to move quickly, minimize investment in unproven compounds in development, and maximize the utilization of facilities. 


    However, anyone who has developed or implemented processes in multiple organizations knows that the concept of a “standard platform” is relative. As in many things, the devil is in the details: equipment choices and specifications, raw materials and consumables, and even the understanding of what is acceptable, and what is not acceptable, changes from organization to organization. The efficiency that is gained when a biopharma company has standardized its processes down to the final buffer can be lost when the process undergoes tech transfer. In fact, the highly prescriptive reliance on being true to a platform in every detail can often lead to significant inefficiencies. For instance, if a critical raw material is difficult to obtain, or a proprietary media formulation must be accessed from a vendor, this one fact could lead to delays and incur greater expense. Furthermore, the lack of standardization of product offerings from vendors can result in a reluctance to change. How many organizations are willing to try a different container/closure system after years of real-time stability data? 


    Biopharma Company Perspective


    If you are seeking to outsource some, or all, of your production, you may (or may not) have established a platform system for production of your products. If you have a platform system, then the barriers to change can be significant, and the pressure to conform to this platform can be extremely high. If you can run your process at a CMO exactly as it was run in the past, and exactly as you wish it to be run in the future, your job is much easier. Your regulatory burden is lower, as you will have much less information to provide regulators during the site change. In addition, you have a very high chance of success under controlled conditions; by controlling change, you have controlled your risk. Given the inherent risks in drug development in general, every risk parameter you control is one less headache in the future. So you really want to run the process at the CMO exactly as it would run “at home.” 


    While I was with a biopharma firm, my management colleagues and I always looked for any possible opportunities to standardize processes. By doing this, we used fewer resources to develop a platform process, it took less time, and it enabled us to handle a much larger portfolio of projects. We standardized vendors, materials, methods, and anything else we could find. The key drive was to have as little product-specific effort expended as possible. 


    CMO Perspective


    When you are working for the CMO, you can’t anticipate all possibilities when you design your facility and your processes. As mentioned above, offering greater flexibility can be expensive. Having every possible piece of equipment, and every possible component or consumable at your fingertips would be very difficult and inefficient. You have to anticipate the majority of your clients’ needs, and, applying the 80:20 Rule, try to cover 80% of the possibilities. Ideally, you have most of the equipment and materials that a client may need, and you have a well-prepared supply-chain group to procure those things that are not readily at hand. Achieving this can even be challenging, if you are working with evolving technologies that have yet to be standardized. I heard a potential client once claim, “Oh, this will be easy; our project is very platform,” only to find out that it was unlike any platform any of us had ever seen before! In addition, as technologies evolve, a CMO must keep current in order to have the latest offering available, yet must do so without wasting time and money on technological dead-ends. 


    Even more troubling to CMOs is the fact that they, like regulators, have seen many platforms. CMOs often have a very keen insight into the many different ways one can approach the same problem. In other words, the CMO may actually know a better way. Its ability to influence a client varies, of course, and it is difficult to discern if a client has deliberately chosen the platform, or if it evolved by default, but then again, the client might be open to improvements. 


    Although bound by confidentiality between clients, patterns in practices do emerge, and if you have seen enough platforms, you know that none is perfect, and each must sub-optimize something to achieve standardization. Common problems often have multiple solutions, and since a CMO is primarily driven to help the client succeed, knowledge of what works best in terms of equipment and facility may give the CMO significant insight into the limitations of a client’s platform.


    The key to success is to adapt as necessary. In an ideal client-CMO relationship, each party will bring a wealth of knowledge and experience to the table. I have learned something from every project I have participated in, whether as a client or as a service provider. Being open to the possibilities of change, recognizing improvements, and even working together to define expectations for external providers can bring great benefits to the collaboration, and indeed to the industry. Vendors will respond to market demands, and two voices are stronger than one.

    The possibility of change itself is not inherently bad, either. In fact, a process that performs well under a variety of production scenarios is inherently more robust, and provides greater assurance of consistency in the future. The more your process performs well under different conditions, the more likely it is to do so later. The biopharmaceutical production industry is far from fully mature, and improvements and innovations are taking place all the time. Ideally, a client-CMO relationship would enhance both organizations, and strengthen the fundamental platform on which a successful collaborative relationship is built. 


     

    Morrey Atkinson is chief scientific officer and vice president of R&D at Cook Pharmica, a bio-CDMO based in Bloomington, IN. Prior to joining Cook Pharmica, he spent nine years at Eli Lilly & Co., as both head of Biotechnology Manufacturing Sciences and Technology in Kinsale, Ireland and director of Bioprocess R&D in Indianapolis, IN. Having experience in both of the sponsor and provider areas, he has a unique perspective on the challenges that drug companies face, as well as the outsourcing services that support them. Morrey will occasionally discuss biopharma issues in this space from both of these viewpoints. To comment on this article or suggest a topic of interest, please contact him at morrey.atkinson@cookpharmica.com.

    Related Searches
    • Stability
    • Tech Transfer
    • Manufacturing
    • CDMO
    Suggested For You
    New CDMO Vector BioMed Launches Operations New CDMO Vector BioMed Launches Operations
    First Patient is Dosed with Triumvira First Patient is Dosed with Triumvira's Investigational TAC-T Cell Adoptive Immunotherapy
    Naobios to Manufacture FluGen’s M2SR Flu Vax Candidate  Naobios to Manufacture FluGen’s M2SR Flu Vax Candidate
    CuriRx Launches CuriLytics Platform for Biotherapeutic Development CuriRx Launches CuriLytics Platform for Biotherapeutic Development
    Oxford Bio Advances Boehringer Oncology Candidate Oxford Bio Advances Boehringer Oncology Candidate
    Asychem Partners with LaNova Medicines Asychem Partners with LaNova Medicines
    Symbiosis Completes Successful MHRA Audit Symbiosis Completes Successful MHRA Audit
    Syneos Health Acquires Clinical Trial Recruitment and Retention Company StudyKIK Syneos Health Acquires Clinical Trial Recruitment and Retention Company StudyKIK
    LabVantage Solutions Launches LabVantage Enterprise SaaS LabVantage Solutions Launches LabVantage Enterprise SaaS
    Hookipa Enters Clinical Collaboration & Supply Agreement with Merck & Co. Hookipa Enters Clinical Collaboration & Supply Agreement with Merck & Co.
    CEO Spotlight: Gaston Salinas, Botanical Solution Inc. CEO Spotlight: Gaston Salinas, Botanical Solution Inc.
    Aurion Biotech Makes Strategic Investments in Manufacturing Aurion Biotech Makes Strategic Investments in Manufacturing
    Frontage Expands Early Drug Discovery Services Frontage Expands Early Drug Discovery Services
    FUJIFILM Diosynth Biotechnologies, NeuExcell Enter Gene Therapy Mfg. Pact FUJIFILM Diosynth Biotechnologies, NeuExcell Enter Gene Therapy Mfg. Pact
    UK Govt. Terminates Valneva COVID Vax Agreement UK Govt. Terminates Valneva COVID Vax Agreement

    Related Breaking News

    • Biologics, Proteins, Vaccines | Breaking News | Industry News
      New CDMO Vector BioMed Launches Operations

      New CDMO Vector BioMed Launches Operations

      The biomanufacturing company’s mission is to provide access to high-quality lentiviral vectors and address the vector supply bottleneck.
      02.01.23

    • Breaking News | Clinical Trials
      First Patient is Dosed with Triumvira

      First Patient is Dosed with Triumvira's Investigational TAC-T Cell Adoptive Immunotherapy

      TAC01-HER2 was developed for the treatment of HER2-overexpressing cancers.
      09.21.21

    • Biologics, Proteins, Vaccines | Breaking News | cGMP Manufacture | Clinical Trial Materials | Industry News
      Naobios to Manufacture FluGen’s M2SR Flu Vax Candidate

      Naobios to Manufacture FluGen’s M2SR Flu Vax Candidate

      Will initiate the GMP manufacturing of the clinical batches of FluGen’s M2SR influenza vaccine candidate for upcoming clinical trials.
      09.21.21


    • Biologics, Proteins, Vaccines | Breaking News | Drug Development | Industry News
      CuriRx Launches CuriLytics Platform for Biotherapeutic Development

      CuriRx Launches CuriLytics Platform for Biotherapeutic Development

      To provide CMC analytical services to support complex biotherapeutic development using high resolution mass spectrometry.
      09.21.21

    • Breaking News | Collaborations & Alliances | Drug Development | Industry News
      Oxford Bio Advances Boehringer Oncology Candidate

      Oxford Bio Advances Boehringer Oncology Candidate

      Receives another milestone payment from Boehringer Ingelheim for progressing a second oncology drug candidate (BI 765049) into the clinic.
      09.20.21

    Loading, Please Wait..
    Trending
    • Aurigene Expands Biologics CDMO Capacity
    • Astellas To Transfer Manufacturing Plant To Delpharm
    • Catalent Adds New Cryogenic Capabilities At Japanese Facility
    • Thermo Fisher Expands Steriles Facility In Asia-Pacific Region
    • Lifecore Biomedical Enters Into $150M New Financing Deal
    Breaking News
    • Meiji Seika Pharma, Adcock Ingram Pharma Complete Construction of New Manufacturing Facility
    • JSR Life Sciences Consolidates KBI Biopharma and Selexis SA
    • Charles River, Wheeler Bio Partner to Operate RightSource Laboratory
    • Cellular Origins Launches Robotic Platform for Scalable Manufacture of Advanced Therapies
    • Waters Corp. Acquires Light Scattering Company Wyatt Technology
    View Breaking News >
    CURRENT ISSUE

    May 2023

    • New Modalities Hog the Limelight
    • Cell and Gene Therapy is Coming of Age
    • Demand Surges for Cell and Gene Therapy Contract Manufacturing
    • Embracing a New Reality
    • Japan: A Unique Opportunity for Regenerative Medicines and Cell & Gene Therapies
    • Single-Use Technologies Enable Biologic Scaling
    • Get Smart: Integrating PAT Data into Existing Biotech Data Infrastructures
    • FTEs in Drug Discovery
    • Digital Transformation in Pharma
    • What is a Manufacturing Ecosystem and Why are They Growing?
    • View More >

    Cookies help us to provide you with an excellent service. By using our website, you declare yourself in agreement with our use of cookies.
    You can obtain detailed information about the use of cookies on our website by clicking on "More information”.

    • About Us
    • Privacy Policy
    • Terms And Conditions
    • Contact Us

    follow us

    Subscribe
    Nutraceuticals World

    Latest Breaking News From Nutraceuticals World

    Verdure Sciences Receives Award for Sustainable, Ethical Turmeric Sourcing
    BGG Receives Patent for Saw Palmetto ID Method
    Premium Label & Packaging Solutions Receives Safe Quality Food (SQF) Certification
    Coatings World

    Latest Breaking News From Coatings World

    Brand Finance: Post-COVID Recovery Slows for Chemicals Industry Battling Energy Crisis
    BCF Calls for Greater Urgency on REACH Impasse
    MNYCA Hosts Afternoon Baseball Event
    Medical Product Outsourcing

    Latest Breaking News From Medical Product Outsourcing

    CareDx, Miromatrix Collaborate on Bioengineered Organs Research
    Capitainer Releases to Market its Fully Automated Sample Handler
    Titan Medical Licenses Most IP to Intuitive; CEO Steps Down
    Contract Pharma

    Latest Breaking News From Contract Pharma

    Meiji Seika Pharma, Adcock Ingram Pharma Complete Construction of New Manufacturing Facility
    JSR Life Sciences Consolidates KBI Biopharma and Selexis SA
    Charles River, Wheeler Bio Partner to Operate RightSource Laboratory
    Beauty Packaging

    Latest Breaking News From Beauty Packaging

    Stetson Introduces Men’s Grooming Portfolio
    Two Executives Depart from Unilever Amid CEO Transition
    L’Oréal Paris Welcomes Thuso Mbedu as Brand Ambassador
    Happi

    Latest Breaking News From Happi

    Beautycounter Appoints Board Director Mindy Mackenzie Interim CEO
    Unilever Ventures’ Backs Selva Ventures in $34 Million Fund for Early-Stage CPG Brands
    Two Executives Depart from Unilever Amid CEO Transition
    Ink World

    Latest Breaking News From Ink World

    ACTEGA, Makro Labelling to Advance Signite Technology
    BCF Requests Greater Urgency on REACH Impasse
    Updated Method Published for Entire BASF Product Portfolio
    Label & Narrow Web

    Latest Breaking News From Label & Narrow Web

    ACTEGA teams with Makro Labelling to advance Signite technology
    Constantia Flexibles and SB Packagings commence joint venture
    Inland donates new VersaStudio printer to local high school
    Nonwovens Industry

    Latest Breaking News From Nonwovens Industry

    Mann+Hummel Names President Air Filtration Americas
    KNH Launches Eco-Friendly Menstrual Pads
    Niine Introduces India's First PLA-Based Sanitary Pads
    Orthopedic Design & Technology

    Latest Breaking News From Orthopedic Design & Technology

    Enrollment Completed in Anika Therapeutics' Hyalofast Study
    Exactech Releases Next-Gen GPS Shoulder
    Data Shows Favorable Survivorship of MISHA Knee System & Reduction of Arthroplasty Risk in Patients
    Printed Electronics Now

    Latest Breaking News From Printed Electronics Now

    onsemi Presents Path to Accelerate Revenue Growth
    STMicroelectronics Introduces Waterproof MEMS Pressure Sensor
    Graphene Flagship to Join Euro Nano Forum 2023

    Copyright © 2023 Rodman Media. All rights reserved. Use of this constitutes acceptance of our privacy policy The material on this site may not be reproduced, distributed, transmitted, or otherwise used, except with the prior written permission of Rodman Media.

    AD BLOCKER DETECTED

    Our website is made possible by displaying online advertisements to our visitors.
    Please consider supporting us by disabling your ad blocker.


    FREE SUBSCRIPTION Already a subscriber? Login